685 related articles for article (PubMed ID: 32855385)
1. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Meng F; Xu R; Wang S; Xu Z; Zhang C; Li Y; Yang T; Shi L; Fu J; Jiang T; Huang L; Zhao P; Yuan X; Fan X; Zhang JY; Song J; Zhang D; Jiao Y; Liu L; Zhou C; Maeurer M; Zumla A; Shi M; Wang FS
Signal Transduct Target Ther; 2020 Aug; 5(1):172. PubMed ID: 32855385
[TBL] [Abstract][Full Text] [Related]
2. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Atluri S; Manchikanti L; Hirsch JA
Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
[TBL] [Abstract][Full Text] [Related]
3. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.
Zhang Y; Ding J; Ren S; Wang W; Yang Y; Li S; Meng M; Wu T; Liu D; Tian S; Tian H; Chen S; Zhou C
Stem Cell Res Ther; 2020 May; 11(1):207. PubMed ID: 32460839
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
5. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells.
Shu L; Niu C; Li R; Huang T; Wang Y; Huang M; Ji N; Zheng Y; Chen X; Shi L; Wu M; Deng K; Wei J; Wang X; Cao Y; Yan J; Feng G
Stem Cell Res Ther; 2020 Aug; 11(1):361. PubMed ID: 32811531
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.
Golchin A; Seyedjafari E; Ardeshirylajimi A
Stem Cell Rev Rep; 2020 Jun; 16(3):427-433. PubMed ID: 32281052
[TBL] [Abstract][Full Text] [Related]
8. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.
Shi L; Huang H; Lu X; Yan X; Jiang X; Xu R; Wang S; Zhang C; Yuan X; Xu Z; Huang L; Fu JL; Li Y; Zhang Y; Yao WQ; Liu T; Song J; Sun L; Yang F; Zhang X; Zhang B; Shi M; Meng F; Song Y; Yu Y; Wen J; Li Q; Mao Q; Maeurer M; Zumla A; Yao C; Xie WF; Wang FS
Signal Transduct Target Ther; 2021 Feb; 6(1):58. PubMed ID: 33568628
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019.
Kowitdamrong E; Puthanakit T; Jantarabenjakul W; Prompetchara E; Suchartlikitwong P; Putcharoen O; Hirankarn N
PLoS One; 2020; 15(10):e0240502. PubMed ID: 33035234
[TBL] [Abstract][Full Text] [Related]
11. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Lanzoni G; Linetsky E; Correa D; Messinger Cayetano S; Alvarez RA; Kouroupis D; Alvarez Gil A; Poggioli R; Ruiz P; Marttos AC; Hirani K; Bell CA; Kusack H; Rafkin L; Baidal D; Pastewski A; Gawri K; Leñero C; Mantero AMA; Metalonis SW; Wang X; Roque L; Masters B; Kenyon NS; Ginzburg E; Xu X; Tan J; Caplan AI; Glassberg MK; Alejandro R; Ricordi C
Stem Cells Transl Med; 2021 May; 10(5):660-673. PubMed ID: 33400390
[TBL] [Abstract][Full Text] [Related]
12. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
Zumla A; Wang FS; Ippolito G; Petrosillo N; Agrati C; Azhar EI; Chang C; El-Kafrawy SA; Osman M; Zitvogel L; Galle PR; Locatelli F; Gorman E; Cordon-Cardo C; O'Kane C; McAuley D; Maeurer M
Int J Infect Dis; 2020 Jul; 96():431-439. PubMed ID: 32425638
[TBL] [Abstract][Full Text] [Related]
13. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
14. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report.
Liang B; Chen J; Li T; Wu H; Yang W; Li Y; Li J; Yu C; Nie F; Ma Z; Yang M; Xiao M; Nie P; Gao Y; Qian C; Hu M
Medicine (Baltimore); 2020 Jul; 99(31):e21429. PubMed ID: 32756149
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
Stalder G; Alberio L
Blood; 2020 Aug; 136(7):915. PubMed ID: 32790855
[No Abstract] [Full Text] [Related]
16. Patterns of IgG and IgM antibody response in COVID-19 patients.
Liu X; Wang J; Xu X; Liao G; Chen Y; Hu CH
Emerg Microbes Infect; 2020 Dec; 9(1):1269-1274. PubMed ID: 32515684
[No Abstract] [Full Text] [Related]
17. Antibody responses to SARS-CoV-2 in patients with COVID-19.
Long QX; Liu BZ; Deng HJ; Wu GC; Deng K; Chen YK; Liao P; Qiu JF; Lin Y; Cai XF; Wang DQ; Hu Y; Ren JH; Tang N; Xu YY; Yu LH; Mo Z; Gong F; Zhang XL; Tian WG; Hu L; Zhang XX; Xiang JL; Du HX; Liu HW; Lang CH; Luo XH; Wu SB; Cui XP; Zhou Z; Zhu MM; Wang J; Xue CJ; Li XF; Wang L; Li ZJ; Wang K; Niu CC; Yang QJ; Tang XJ; Zhang Y; Liu XM; Li JJ; Zhang DC; Zhang F; Liu P; Yuan J; Li Q; Hu JL; Chen J; Huang AL
Nat Med; 2020 Jun; 26(6):845-848. PubMed ID: 32350462
[TBL] [Abstract][Full Text] [Related]
18. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
[TBL] [Abstract][Full Text] [Related]
19. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.
Zeng H; Wang D; Nie J; Liang H; Gu J; Zhao A; Xu L; Lang C; Cui X; Guo X; Zhou C; Li H; Guo B; Zhang J; Wang Q; Fang L; Liu W; Huang Y; Mao W; Chen Y; Zou Q
Signal Transduct Target Ther; 2020 Oct; 5(1):219. PubMed ID: 33024082
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.
Jayaramayya K; Mahalaxmi I; Subramaniam MD; Raj N; Dayem AA; Lim KM; Kim SJ; An JY; Lee Y; Choi Y; Raj A; Cho SG; Vellingiri B
BMB Rep; 2020 Aug; 53(8):400-412. PubMed ID: 32731913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
